Skip to Content Skip to Content

Immunology

Why Penn research powers many FDA-approved treatments
Aerial image of Penn Medicine staff in the atrium celebrating.

On August 30, 2017, faculty and staff at the Perelman Center for Advanced Medicine gathered for a “flash mob” celebration of the the FDA approval of a Penn Medicine-developed personalized cellular immune therapy.

(Image: Courtesy of Penn Medicine News)

Why Penn research powers many FDA-approved treatments

Since 2017, the FDA approved more than two dozen new therapies with roots at Penn Medicine—almost half of which are first-in-class for their indications.

Karen L. Brooks for Penn Medicine Magazine

A potential strategy to improve T cell therapy in solid tumors
Microscopic view of a DNA strand.

Image: Courtesy of Penn Medicine News

A potential strategy to improve T cell therapy in solid tumors

A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors.

From Penn Medicine News